Blood Collection Market Size was valued at USD 4.806 billion in 2023. The Blood Collection market industry is projected to grow from USD 5.132 Billion in 2024 to USD 8.134929 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.93% during the forecast period (2024 - 2032). Rising awareness about blood collection techniques and rising demand for early diagnosis of chronic conditionsare the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
In March 2024, BD (Becton, Dickinson, and Company) introduced the BD Vacutainer® UltraTouch™ Push Button Blood Collection Set in India. This new product aims to reduce patient pain and discomfort during blood collection by allowing for a single successful prick. The BD Vacutainer® UltraTouch™ Push Button Blood Collection Set incorporates BD RightGauge™ technology, which allows for the utilization of a finer needle during blood collection. Additionally, the set utilizes BD PentaPoint™ Technology, resulting in a notable reduction in the level of discomfort experienced by the patient during needle insertion. It is important to note that the BD Vacutainer® UltraTouch™ is equipped with BD Push Button Technology, which decreases the likelihood of needle injuries by 88%. In recent years, patients have increasingly sought not only reliable and prompt test results, but also an outstanding experience from medical laboratories. Blood collection has become a crucial initial stage in the continuum of patient care. BD, a prominent player in the field of producing comprehensive pre-analytical solutions, is dedicated to creating cutting-edge technology that facilitate a more comfortable, secure, and expedited blood collection process for patients.
In April 2024, Labcorp, a global life sciences business, introduced the first commercially accessible blood biomarker test for glial fibrillary acidic protein (GFAP) in the United States. This test provides a novel means of identifying neurodegenerative disorders and brain traumas at an early stage. The novel instrument utilizes highly sensitive immunoassay technology to quantify GFAP, an early-stage biomarker of brain injury, from a straightforward blood sample. Now included in Labcorp's comprehensive neurology collection, this test is a key breakthrough in diagnosing and treating neurodegenerative conditions like Alzheimer's, multiple sclerosis, glioblastoma, and traumatic brain injury (TBI). The test can be conducted in diverse environments, such as hospitals, physician offices, and Labcorp's vast network of patient service centers. Labcorp's introduction of the GFAP biomarker test represents a noteworthy achievement, further solidifying our position as a frontrunner in the fast advancing field of blood-based biomarkers for neurodegenerative illnesses.
The increasing number of hospitals, ambulatory surgical centers, and diagnostic laboratories worldwide is expected to drive the growth of the blood collection devices market. The rise in hospitals and other healthcare facilities has increased the demand for blood collection devices. In addition, the growing awareness about the safety and convenience of using advanced blood collection devices is also expected to fuel the growth of this market. Furthermore, increasing government initiatives to promote the use of advanced medical technologies is also contributing to the growth of the market CAGR.
Additionally, the blood collection devices market is expected to grow significantly due to the increasing demand for apheresis for blood component separations. Apheresis is a medical procedure in which a person's blood is passed through a device that separates one particular component. This component is then collected, and the remaining components are returned to the body. This procedure is increasingly used to collect plasma, red blood cells, platelets, and other components for therapeutic purposes. Furthermore, the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases further drives market growth as it enables accurate collection of blood components to treat such diseases. Additionally, increasing public awareness regarding the benefits of blood component separations is a major factor propelling the market's growth. This factor drives the Blood Collection market revenue.
The Blood Collection market segmentation, based on type, includes capillary, venous, and vacuum. The venous segment dominated the market due to its ease of use and the ability to collect larger volumes of blood for testing. Moreover, venous blood collection is preferred for certain tests requiring serum or plasma, which can be obtained through centrifugation of the collected blood.
Based on product, the Blood Collection market segmentation includes blood collection devices, tubes, needles and syringes, and lancets. The blood collection devices segment dominated the market; Blood samples are collected in blood collection tubes, sometimes known as vacutainers, for analysis. They are made of glass or plastic, with a rubber stopper that creates a vacuum inside the tube. This allowed the exact amount of blood to be extracted from the patient, including chemicals that help stabilize and preserve the specimen before testing. Blood collection tubes give an advantage for separating different components of blood. All of these factors are expected to drive revenue growth of this segment over the forecast period.
The Blood Collection market segmentation, based on method, includes automated and manual. The automated segment dominated the market due to capital investments in automated blood collection methods being very high compared to manual blood collection. Also, therapeutic apheresis cost is very high as it includes the additional cost of disposables. Thus, due to their high costs, adoption of this automated blood collection method is very low compared to manual blood collection methods in countries such as China and India. Nevertheless, technological advancement, which helps blood collection and separation, improves clinical efficiency and sample quality, offering favorable growth opportunities for this segment during the forecast period.
Figure 1 Blood Collection Market, by Method, 2023 & 2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American blood collection market will dominate this market, owing to well-developed healthcare infrastructure, increased R&D activities, and the presence of leading clinical diagnostics companies in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 BLOOD COLLECTION MARKET SHARE BY REGION 2023 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Blood Collection market accounts for the second-largest market share due to theincreasing number of blood donation activities. The presence of key market players in this Region is expected to drive market expansion. Further, the German Blood Collection market held the largest market share, and the UK Blood Collection market was the fastest-growing market in the European Region.
The Asia-Pacific Blood Collection Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due torising disposable income and escalating prevalence of sepsis and HAI in this Region. Also, the growing presence of leading manufacturers in this Region is expected to contribute to the growth. Moreover, China’s Blood Collection market held the largest market share, and the Indian Blood Collection market was the fastest-growing market in the Asia-Pacific region.
Blood Collection Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Blood Collection market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The blood collection industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Blood Collection industry to benefit clients and increase the market sector. In recent years, the Blood Collection industry has offered some of the most significant advantages to medicine. Major players in the Blood Collection market, including BD, Medtronic, Terumo, Haemonetics, Fresenius, Nipro Medical, Kawasumi Laboratories, F.L. Medical, Greiner Holding, Grifols, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., HTL-STREFA S.A., Sarstedt AG & Co., and others, are attempting to increase market demand by investing in research and development operations.
Becton, Dickinson, and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies. BD (Becton, Dickinson, and Company) released UltraSafePlus 2.25 mL, a new needle guard solution that improves the delivery of drugs and other biologic solutions.
Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to significantly improve critical laboratory tests' accuracy, consistency, and predictability. Magnolia Medical invented and patented the initial specimen diversion technique (ISDT™) and device (ISDD®) for blood culture collection and contamination prevention. The company has amassed an intellectual property portfolio including more than 70 issued method, apparatus, and design patents with more than 50 additional patent applications pending.Magnolia Medical launched Steripath Gen2 with an integrated syringe for patients with difficult intravenous access (DIVA) or the 'hard stick' patient population.
Key Companies in the blood collection market include
Blood Collection IndustryDevelopments
July 2020 Magnolia Medical launches Steripath Gen2 with an integrated syringe, addressed to the patients with difficult intravenous access (DIVA) or the 'hard stick' patient population
January 2018 DBS System launches the HemaXis DB micro blood collection device with FDA listing in the United States
| Report Attribute/Metric | Details |
| Market Size2023 | USD 4.806 billion |
| Market Size 2024 | USD 5.132 billion |
| Market Size2032 | USD 8.1349 billion |
| Compound Annual Growth Rate (CAGR) | 5.93%(2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, Method, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | BD, Medtronic, Terumo, Haemonetics, Fresenius, Nipro Medical, Kawasumi Laboratories, F.L. Medical, Greiner Holding, Grifols, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., HTL-STREFA S.A., Sarstedt AG & Co. |
| Key Market Opportunities | Rising awareness about blood collection techniques |
| Key Market Dynamics | Developing healthcare infrastructure Rising demand for early diagnosis of chronic conditions |
Blood Collection Market Highlights:
Frequently Asked Questions (FAQ) :
The Blood Collection market size was valued at USD 4.806 Billion in 2023.
The market is projected to grow at a CAGR of 5.93%during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market areBD, Medtronic, Terumo, Haemonetics, Fresenius, Nipro Medical, Kawasumi Laboratories, F.L. Medical, Greiner Holding, Grifols, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., HTL-STREFA S.A., Sarstedt AG & Co.
The Venous Blood Collection category dominated the market in 2022.
Automated had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
